Overview

A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone

Status:
Completed

Trial end date:
2012-01-01

Target enrollment:

Participant gender:

Summary

This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Erlotinib Hydrochloride
Sunitinib